Ranked by possible gain

Prices: market data get_latest_stock_price, close of 2026-09-22 (fetched 2026-09-23)

Companies28
Could go up17 of 28
Estimated targets4

All companies

price now, target
#CompanyPriceTargetPossible gainWorst → bestWhy it could rise
1HELP
from notes
$13.71$28.00+104%
Worst $2.30Best $54.00

One molecule, one trial, one quarter. HLP003 (deuterated psilocin) for adjunctive MDD reads out topline from APPROACH in Q4 2026; $166.4m of cash at 2026-06-30 funds the company past it with ~4.5 quarters of runway. The company's own Phase 2 in GAD is the warning: its sub-therapeutic 2mg control arm produced a 30% responder rate against 59% at 20mg, and APPROACH uses inactive placebo with a drug that produces 90 minutes of unmistakable acute effect. How the placebo arm behaves is the thesis.

Events to watch: APPROACH topline efficacy, Q4 2026, and specifically the placebo arm's own MADRS movement; the HLP004 next-study design, committed by end of Q3 2026; whether the unused $100m ATM is drawn at $13.71 rather than at June's $4.85; confirmation of the apparent shift from foreign-private-issuer to domestic reporting (first-ever S-8, Form 3s, Form 4s and 13Ds all in September 2026); a permanent CEO appointment - the company is interim-led into the readout.

How we got the target

NOT an out-year earnings model - there are no earnings. The scorecard's S7 scenario table around the pivotal readout, with NO probability attached to any column: bear values the residual as ~$120m of net cash plus an option on HLP004 and the IP over 78m shares; base and bull apply a 2.4x and 4.6x re-rating of today's ~$0.87bn enterprise value over 85m shares, assuming the unused $100m ATM is drawn into strength. The re-rating multiples are a judgement, not an observation. Time frame: the APPROACH Phase 3 readout, Q4 2026.

2AVGO
estimated
$364.54$540+48%
Worst $214Best $640

Priced at ~12x management's FY28 EPS target: the market is discounting the AI revenue guides ($115bn FY27, $230bn FY28 AI). If the custom-accelerator schedule is delivered, the earnings arrive and the discount closes.

Events to watch: Quarterly AI revenue against the $115bn FY27 guide; Singapore substrate capacity unlocking in FY27; customer-concentration disclosure (one distributor at 50% of Q3 FY26 revenue) not rising further.

How we got the target

Management's own FY28 EPS of >$30 (the dossier's model lands on ~$30 independently) × 18x, an assumed multiple below today's ~20.6x on FY27. Bear: the dossier's '40%+ drawdown' from ~$357. Bull: EPS $32 × 20x. Time frame: FY2028 (Oct 2028).

31913.HK
from notes
$37.38$49.90+33%
Worst $25.10Best $76.00

13.4x LTM EPS and 9.2x EV/EBIT Adjusted (ex-leases) for a group whose two brands swapped roles: Miu Miu went from +34.8% (FY2025) to +2.5% (H1 2026) while the Prada brand re-accelerated to +6.3% in Q2 2026 on full-price like-for-like. Versace (USD 1,395m, closed 2025-12-02) is guided to flat losses in 2026 and took the H1 margin from 22.6% to 17.4%; the variant is that this is the trough, on a flat 2,558.8m share count and 0.43x pre-lease leverage. Governance discount is real: 80% family control, float at the 20% waiver minimum, a steady flow of real-estate deals with the founders' vehicles.

Events to watch: Q3 2026 revenue update ~late October 2026 (DERIVED from cadence: 2025-10-23) — Miu Miu's quarter first (forward growth dodged on the Q1 and Q2 calls), then Prada-brand growth against Q2's +6.3%; FY2026 results ~early March 2027 with Versace's FY2026 loss against 'not dissimilar' guidance; Pieter Mulier's first Versace collection, May 2027; any Milan prosecutors' action on the 2025-12-04 labour-exploitation document request naming Prada and Versace; any further connected-transaction property deal with a family vehicle.

How we got the target

Dossier model table (1913.HK/dossier-2026-09-23.md §5), P/E on FY2028 EPS: organic base (FY2025 net revenues less Versace's one month, EUR 5,652m) grown +1%/+5%/+8% a year at 20%/23%/24% EBIT margin, Versace EUR 600m/650m/800m revenue at -EUR 80m/breakeven/+8% margin, EUR 160m net financial expense, 27% tax, 2,558.8m shares; EPS EUR 0.254/0.371/0.446 at 11x/15x/19x = EUR 2.79/5.56/8.46. Reported in EUR, converted to HKD at EUR/HKD 8.9789 (market data FX:EURHKD 2026-09-22 close). Price is market data's HKEX:1913 2026-09-22 close. Dividends (~4% yield) are NOT in the figures. Time frame: FY2028 (Dec 2028).

4LNC
from notes
$41.01$53.00+29%
Worst $29.00Best $80.00

0.76x its own book including AOCI and ~4.7x annualised H1 2026 adjusted operating EPS; the $23.71-a-share gap to book ex-AOCI is an $8.5bn unrealised bond loss that accretes back at par. The base case is LNC getting back to its own book, not a re-rating. The constraint nobody models: Bain's $44.00 floor sits above the market price and encumbers four-fifths of the $714m buyback authority.

Events to watch: Q3 results ~2026-10-29 — the annual assumption review (charged net income in two of the last three years) and the leverage ratio against the 25% target now that $437m of preferred left the stack and $500m of 2056 subordinated notes stayed in it; any Schedule 13D/A showing LNC buying Bain's stock at $44; the permanent CFO hire; the 2026-09-15 short-interest settlement published 2026-09-24 after +33% at 2026-08-31.

How we got the target

Scorecard model table: 2028E adjusted operating EPS bear $6.45 / base $8.80 / bull $10.71 at 4.5x / 6.0x / 7.5x. Price is the 2026-09-22 close from market data get_stock_prices (NYSE:LNC), not get_latest_stock_price. Time frame: 2028 model line.

5NVDA
estimated
$228.87$295+29%
Worst $125Best $429

On management's own numbers it trades at ~14x FY28 EPS — the dossier calls it cheap, and says that is the tell: the market is pricing a real chance the FY28 guide misses because a rising share of demand is underwritten by NVIDIA itself.

Events to watch: FY28 ~70% growth guide held or raised; supply commitments ($279bn) not falling; gross margin holding the 71-72% Q4 trough then 72-73%; receivables growth slowing.

How we got the target

The dossier's base FY28 EPS ~$16.4 (management's ~70% growth guide met) × 18x, an assumed multiple below today's ~23x on FY27. Bear: the dossier's '40-50% drawdown'. Bull: EPS ~$19.5 × 22x. Time frame: FY2028 (Jan 2028).

6ZS
estimated
$210.18$260+24%
Worst $149Best $388

Organic net new ARR accelerated 7% → 10% → 17% through FY26 while the FY27 guide embeds ~4%; if Security for AI and Agentic SOC land, 17% is a floor and the stock re-rates from ~7.7x EV/FY27 revenue.

Events to watch: Investor Day 2026-10-06 (FY28-30 targets, non-seat ACV mix); Q1 FY27 results ~2026-11-24; net new ARR and NRR (kill below 112%).

How we got the target

The dossier's illustrative FY29 scenario EVs (bear $25bn / base $45bn / bull $68bn) plus $1.77bn net cash, divided by ~180m diluted shares. The dossier itself calls these 'illustrative, not a model'. Time frame: FY2029 (Jul 2029) — beyond two years.

7AIG
from notes
$75.18$93.00+24%
Worst $60.00Best $130

The only P&C name in the cluster at or below book (P/B 0.97). The base case is AIG keeps trading at book while earning 11-12% on it; the Corebridge exit is done and underwriting has started growing again.

Events to watch: Q3 results ~2026-11-03; buyback pace ($2.6bn authority left) against the premium trend; Item 5.02 8-Ks after two senior departures in fifteen days.

How we got the target

Scorecard model table: base ~$93 ('does not require a re-rating'). The scorecard's summary line says ~$92. Time frame: 2028 model line.

8AX
from notes
$89.13$110+23%
Worst $44.00Best $150

10x forward earnings for a bank compounding book value; the acquired Capital One IRA deposits are cheap funding if they arrived, and NIM above 4.6% carries the bull case.

Events to watch: Fiscal Q1 2027 10-Q (~2026-10-29): the deposit table (did the ~$1.3bn of IRA balances transfer?) and the purchased-loan marks; efficiency ratio.

How we got the target

Scorecard: base ~$110 at ~1.10x modelled FY2028 book. Time frame: FY2028 (Jun 2028).

9APH
from notes
$82.84$98.00+18%
Worst $42.00Best $147

~20x FY28 model EPS for the connector and cable supplier inside every AI rack; the bull case is AI content per rack compounding, 22% growth holding and a 21.5% margin.

Events to watch: Quarterly IT Datacom growth; the FY2026 10-K re-test of whether acquisitions are 'immaterial in the aggregate' (the SEC asked); buyback nearly exhausted ($411m left).

How we got the target

Scorecard: base ~$98 (~20x FY28E model EPS). Time frame: FY2028.

10HHH
from notes
$66.09$78.00+18%
Worst $48.00Best $112

At 1.00x book HHH is no longer a pure land company: since 2026-06-04 it owns a five-year-old Bermuda specialty insurer (40% of assets) of which a Pershing Square fund's $1.0bn preferred takes up to 49%, whose float Pershing Square now manages without an extra fee and moved within weeks from bonds to a concentrated stock book (32% at 2026-06-30, ~40% by August, target >50%). S&P cut the insurer to BBB on the change of parent [search-summary]. The land bank (MPC EBT $349m → $476m, 2024 → 2025) is being liquidated on purpose to fund it; the base case is book growth, not a re-rating.

Events to watch: Annual meeting 2026-09-30; Q3 results ~2026-11-05 to -11-10 (DERIVED from cadence) — Vantage capital contributions and the equity sleeve against $1.55bn of net reserves; FY2026 10-K (Feb–Mar 2027) with Vantage's first loss-development table; any A.M. Best action; any takedown of the 2026-08-14 universal shelf; trailing MPC EBT against the 2024 $349.1m.

How we got the target

Dossier model table (HHH/dossier-2026-09-23.md §5), book value per share × price-to-book, because the company itself has moved to NAV-style KPIs and has no stable earnings line: base 1.00x ~$78 BVPS (2026-06-30 BVPS $66.39 plus ~$5.5/share a year retained, no issuance); bear 0.75x ~$64 (MPC EBT back to the 2024 ~$350m, Vantage adverse development, a 25% fall in a ~$1.5bn equity sleeve, about half of it borne by the Pershing preferred); bull 1.40x ~$80. No dividend. The company's own $104 'conservative' value is not used. Price is market data's 2026-09-22 close (NYSE:HHH), fetched 2026-09-23. Time frame: mid-2028 (Q2 2028 book).

11CRWV
from notes
$86.76$97.00+12%
Worst $20.00Best $142

A levered equity on a backlog: $103.7bn of RPO and 4.2GW contracted against $35.55bn of debt on $5.02bn of book equity, with $10.6bn of principal due inside eighteen months at effective rates to 15%. The September package is the evidence that matters — $4.2bn of 2.875% converts plus a 35m-share ATM, against an existing stack paying 8.5-9.75%. A market writing 2.875% paper is not pricing the bear case.

Events to watch: Q3 2026 results, early November — whether the 5-10 point contribution-margin uplift management refused to decompose shows up in reported margin; RPO and its 41% 24-month share; the debt table's next-twelve-months column after the convert; any disclosed delay on a contracted gigawatt; whether the material weaknesses are still open in the FY2026 10-K.

How we got the target

Dossier model table, EV/EBITDA rather than earnings because none exist: FY2028 revenue $20bn/$30bn/$34bn at a 40-47% EBITDA margin, 5x/8x/10x, less ~$50bn of net debt, ~600m shares. Bear is ~$20 of option value, not a going-concern value — at 5x the enterprise is worth less than the debt. Time frame: FY2028 (Dec 2028).

12ACGL
from notes
$94.95$105+11%
Worst $77.00Best $130

8.6x 2026E earnings with book compounding and shrinking the share count into a soft market; underwriting remains excellent on a current-accident-year basis.

Events to watch: Q3 2026 10-Q (late Oct): Note 5 prior-year development by tail length — long-tail adverse development was $32m in Q2; buyback pace ($1.95bn in H1).

How we got the target

Scorecard: base ~$105 (~1.14x modelled 2028 BVPS of ~$92). Time frame: 2028 model line.

13ALL
from notes
$229.50$249+8%
Worst $148Best $340

7.4x normalised 2028 EPS on peak-cycle personal-auto profitability; consensus Hold with targets ~$267-300. The bear column ($148) is larger than the upside — asymmetric the wrong way.

Events to watch: September monthly catastrophe release ~2026-10-15 (July-August already $1.43bn vs $558m for all of Q3 2025); Q3 results late Oct/early Nov; buyback pace.

How we got the target

Scorecard model table: base ~$249 ('about 8% of upside'). The summary line says ~$245. Time frame: 2028 (normalised).

14NTAP
from notes
$192.91$209+8%
Worst $126Best $290

Durable pieces (first-party cloud storage +30%, Keystone +65%, 93%-margin support) compound under a cyclical flash-price print; 100% of FCF returned. The stock has already doubled in six months.

Events to watch: INSIGHT 2026-09-29; Q2 FY27 call 2026-12-01 (product GM vs 54-55%, inventory, purchase commitments); NAND contract prices; June 2027 note refinancing.

How we got the target

Dossier's illustrative scenario: base FY29 EPS $12.30 × 17x. Time frame: April 2029 (FY29) — beyond two years.

15KNSL
from notes
$351.83$381+8%
Worst $208Best $560

Best-in-class E&S underwriter (57% loss ratio) at 16x earnings; the bull case needs the 32.7% Commercial Property decline to prove cyclical and ex-property growth to reaccelerate.

Events to watch: Q3 release ~2026-10-22: gross written premium ex-Commercial-Property and the current accident year ex-cat loss ratio; the first buyback in the company's history.

How we got the target

Scorecard: base ~$381 (15.1x 2028E operating EPS). Time frame: 2028.

16OMAB
from notes
$102.45$105+2%
Worst $72.00Best $141

A concession with a tariff framework fixed to 2030 at ~14x earnings; the bull case is passenger traffic reverting to the 2023-25 6-8% growth as airline capacity returns.

Events to watch: Monthly traffic prints (the dossier's buy trigger: two at +4% y/y or better); the 2030 tariff framework staying unamended; the 2026-09-18 unexplained volume spike.

How we got the target

Dossier: base $7.51 EPS per ADS × 14x. Time frame: 2027.

17ASML
from notes
$1,747.90$1,780+2%
Worst $859Best $2,436

The EUV monopoly with a shrinking share count; at ~29x FY28 the base case is roughly priced in, and upside needs the second capacity step (+30% low-NA EUV, +30% more for 2028).

Events to watch: Quarterly orders and 2027 capacity commentary; whether the 'investigated' 2028 +30% is confirmed; TSMC capex discipline as the bubble indicator.

How we got the target

Scorecard: base ~$1,780 (~28.9x FY28E model EPS; converted at EUR/USD 1.14673). Time frame: FY2028.

18PUMP
from notes
$10.03$10.00−0%
Worst $5.00Best $21.00

A frac company becoming a power producer (PROPWR): no return in the base case, a triple if 1.1GW is earning in 2028 — a position-sizing question, not a valuation one. The bear case impairs the equity.

Events to watch: Q3 release (late Oct): the PROPWR contract book reconciled line by line (additions vs capacity coming off contract); EBITDA per MW, which management has not published.

How we got the target

Scorecard model table: base ~$10 at 5.5x 2028 group EBITDA. The summary line says ~$12 and bull ~$24. Time frame: 2028.

19NLY
from notes
$21.44$21.20−1%
Worst $16.10Best $24.70

A 14% yield at 1.06x book, and the yield is the whole base case. From 2021 to 2025 the company reported $12.71/share of EAD while a holder's economic result was about zero — the dividend was paid out of carry and the book absorbed the cycle — and the share count doubled. Since 2023 it has earned double-digit economic returns; the open question is whether that is the new resi-credit/MSR mix or the MBS basis tightening under the GSEs' $200bn purchase mandate.

Events to watch: Q3 2026 results ~2026-10-21 (DERIVED from cadence) — book value per share after a 7.9% fall in the stock since 2026-08-20; EAD against the raised $0.75 dividend; funding of the $442.5m Series I redemption on 2026-10-01; the current-coupon MBS basis (94bp at 2026-06-30) and the GSE mandate's remaining capacity (~$45bn of $200bn settled through May).

How we got the target

Dossier model table (NLY/dossier-2026-09-23.md §5), book value × price-to-book, because an mREIT is valued on book: base 1.05x a flat $20.15 BVPS; bear 0.90x on $17.90 (basis +32bp at the company's own −8.7%-NAV-per-25bp sensitivity, linearly extrapolated); bull 1.15x on $21.50. Price-only: the ~$6.00 of dividends over two years (14.0% yield) is NOT in these figures, so the upside the console computes understates total return by roughly 28 points in the base case. Price is market data's 2026-09-22 close, fetched 2026-09-23. Time frame: mid-2028 (Q2 2028 book).

20ORCL
from notes
$149.20$142−5%
Worst $48.00Best $213

Base lands essentially ON the traded price, so the multiple is not the argument — the share count is. Oracle exhausted a $20bn ATM inside one quarter (141m shares, +5.0%), bought back nothing, and funded $28.5bn of quarterly capex partly with $11.4bn of customer prepayments its own accounting calls a significant financing component. Every further $20bn raise at ~$150 is another ~4.4% of the company. The CFO declined to give a free-cash-flow date.

Events to watch: October 2026 Investor Day — the CFO deferred BOTH the gross-margin and free-cash-flow questions to it; Q2 FY27 results 2026-12-14; the Note 1 prepayment line ($11.4bn vs $0 a year earlier) and RPO ($664bn, 13% inside twelve months); a second ATM authorisation; the Ellison 10b5-1 plan for up to 50m shares running to 2026-10-24.

How we got the target

Dossier model table: FY2028 revenue $85bn/$115bn/$130bn at 20%/31%/33% operating margin, $8bn net interest, 18% tax, 3,150m shares (Series D converted plus one further $20bn-scale raise); EPS $2.25/$7.11/$8.50 at 21x/20x/25x. Time frame: FY2028 (May 2028).

21QCOM
from notes
$198.27$175−12%
Worst $84.00Best $288

The base case is below the price; the upside is the data-centre option — the $5bn FY27 / $15bn FY29 targets are not yet visible in a reported revenue line. Bull: merchant-accelerator share after the mid-2027 launch and a Meta CPU ramp.

Events to watch: Q4 FY26 results 2026-11-04; the FY2026 10-K's accounting for the Amazon warrant; first reported data-centre revenue by early 2027.

How we got the target

Scorecard: base ~$175 (~20x FY28E model EPS). Time frame: FY2028.

22CBRS
from notes
$212.41$177−17%
Worst $55.00Best $300

~62x EV/LTM revenue with no earnings; the base case models below the price and the bull case needs AWS to scale as the term sheet contemplates and customer concentration to broaden.

Events to watch: The Q2 2026 prepared remarks (only a UBS restatement of 'revenue up more than 3x next year' is in hand); 36.1m customer-warrant shares vesting; first S-3 eligibility.

How we got the target

Dossier: base below the traded price; bull $5.50 EPS × 55x on $8bn FY28 revenue. Time frame: FY2028.

23AMD
estimated
$623.77$518−17%
Worst $270Best $900

The expensive one: ~41x FY27 EPS even if Data Center doubles in a year. The price is the option on the second-source thesis, and the OpenAI/Meta warrants (320m shares at $0.01) dilute holders if it works.

Events to watch: Q3 results early Nov; Helios and MI500 ramp; warrant vesting in each 10-Q; the '>$20 EPS' target timeline.

How we got the target

The dossier's base FY27 non-GAAP EPS ~$13.8 × 37.5x, the midpoint of its own bear (30x) and bull (45x) multiples. Bear and bull are the dossier's figures. Time frame: FY2027 (Dec 2027).

24MRVL
from notes
$262.36$203−23%
Worst $98.00Best $259

The base case is below the price even on management's 60%/60% data-centre growth guides; the bull ($259) is roughly today's price. SBC and the NVIDIA preferred (21.8m shares at ~$92) dilute.

Events to watch: Data-centre growth vs the 60% FY27/FY28 guides; Q3 FY27 non-GAAP EPS $1.05-1.15 guide; custom-silicon program wins.

How we got the target

Dossier: base 30x FY28 model EPS $6.76, built from management's own guides. Time frame: FY2028 (Jan 2028).

25DOCN
from notes
$146.00$107−27%
Worst $39.00Best $205

The only cash-generative name in the ai-capex cluster, deliberately trading that status for AI growth. Q2 2026: revenue +29%, gross margin 59.9% to 55.0%, operating income -18%, diluted shares +25.8%, diluted EPS $0.39 to $0.29. At ~104x guided FY2026 non-GAAP EPS the market pays for the transition arriving; the base case here does not reach the current price, and the CFO has twice declined to give free cash flow including lease payments.

Events to watch: One quarter with gross margin flat or up sequentially, operating income growing year over year and a flat diluted share count; an all-in free-cash-flow guide (asked for in two consecutive quarters, not given); the adjusted-FCF margin guide not cut a third time; the 2027 revenue guide formalised above 50%; Access Industries (15.86%, Schedule 13D) not filing a sale.

How we got the target

The scorecard's S7 table: FY2028 revenue $2.10bn/$2.55bn/$3.20bn at 32%/38%/40% adjusted EBITDA margin, valued at 10x/16x/22x EV/adj. EBITDA, less $1.5bn/$1.0bn/$0.5bn of assumed FY2028 net debt, over 135m diluted shares (the FY2026 guide of 122-123m extended for SBC and the remaining converts, assuming no further equity issuance). The multiples are an assumption. Time frame: FY2028.

26NBIS
from notes
$236.12$160−32%
Worst $15.00Best $395

The fastest capital-to-megawatt converter on the list, financed by customers ($5,975.2m of deferred revenue), convertible buyers (carried at $8.5bn, fair value $20.8bn) and NVIDIA ($2.0bn for warrants at $0.0001) rather than by earnings. At ~51x this year's guided adjusted EBITDA the market already pays for the base case; the bear column is what the same model gives if 2027 capacity breaks pricing before the 2026 capex is depreciated.

Events to watch: Deferred revenue holding or rising quarter-on-quarter; the FY2026 ARR guide ($7-9bn) reaffirmed rather than cut; the first quarter in which 2026 capacity earns revenue at a disclosed price per megawatt; the fixed-asset material weakness (controls over depreciation start dates) closed in the FY2026 20-F; no new convert above 5%.

How we got the target

The scorecard's S7 table: FY2028 revenue $8.0bn/$14.0bn/$20.0bn at 30%/40%/45% adjusted EBITDA margin, valued at 8x/12x/16x EV/adj. EBITDA, less $14bn of assumed FY2028 net debt, over ~330m diluted shares. The multiples are an assumption; there is no stable comparable for a business this young. Time frame: FY2028.

27INTC
from notes
$123.86$71.00−43%
Worst $20.00Best $135

The only name in this slot whose base case sits well BELOW the traded price. ~$655bn of market value after the August equity sale, on FY2025 revenue of $52.9bn and no net income, is paying for an external foundry anchor customer that management would not name when asked directly — three weeks before selling $23bn of stock. Reported GAAP EPS is currently inversely geared to the share price through the $15.6bn Escrowed Shares derivative, so the headline loss and the price move together for reasons unrelated to the business.

Events to watch: Intel Foundry third-party revenue in Note 2 of each 10-Q ($293m in Q2 2026 vs $22m a year earlier — the direct measure of the thesis); 14A PDK 0.9 confirmed complete at the October Q3 call, risk production H2 2027, volume 2028; whether Q3 carries another multi-billion Escrowed Shares mark; gross margin staying 'comfortably into the 40s'; a third capital raise before an anchor customer signs.

How we got the target

Dossier model table: FY2028 revenue $65bn/$81bn/$95bn at 40%/48%/53% gross margin, opex ~$18.5bn, net interest ~$2.5bn, 12% tax while the domestic valuation allowance persists, ~5.5bn shares including the escrow release; EPS $0.78/$2.85/$4.50 at 25x/25x/30x. Time frame: FY2028 (Dec 2028).

28ARM
from notes
$333.20$169−49%
Worst $84.00Best $288

~100x+ FY28 earnings; 74% of FY26 revenue growth came from related parties (SoftBank and Arm China) while external revenue grew 7%. Upside needs the AGI CPU and compute-subsystem royalties to inflect.

Events to watch: Royalty growth vs the guided 13%; related-party share of revenue; compute-subsystem adoption; SoftBank's 86.4% as an overhang.

How we got the target

Dossier: base 60x FY28 model EPS $2.81. Only the bull case ($288) comes near today's price. Time frame: FY2028 (Mar 2028).